Abstract
Health services in Africa are being overburdened by a continuous increase of cases of tuberculosis (TB), largely resulting from the large pool of infected individuals becoming co-infected with HIV. To help deal with the situation, TB treatment schedules need to be shorter and simpler, with minimal contact between the patient and the service provider required, if the problems of non-compliance and of ineffective service provision are to be overcome. Various drugs not marketed for use in the treatment of TB are currently under investigation for their potential roles in the simplification or shortening of treatment schedules. These mainly include the long-acting rifamycins and the fluoroquinolones. Furthermore, new drug development is focused on an understanding of the host-pathogen interaction leading to infection, latency and disease. Of these, latency is least understood. The use of molecular diversity and combinatorial chemistry, proteomics, and the use of the whole genome to discover drug targets are expected to produce new lead compounds for turning into drugs to treat active, latent and multi-drug-resistant TB more effectively in the foreseeable future.
References
Jun 1, 1995·Tubercle and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease·S SchwanderR Mugerwa
Oct 1, 1994·Tubercle and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease·L J Gonzalez-MontanerP Olliaro
Jun 20, 1997·Science·D A EdwardsR Langer
Oct 12, 1999·JAMA : the Journal of the American Medical Association·C DyeM C Raviglione
Jul 6, 2000·Nature·C K StoverW R Baker
Oct 20, 2000·BMJ : British Medical Journal·G Mudur
Dec 19, 2000·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·L V SacksS Hurwitz
Apr 24, 2001·American Journal of Respiratory and Critical Care Medicine·R J O'Brien, P P Nunn
Nov 16, 2001·Antimicrobial Agents and Chemotherapy·N LounisJ Grosset
Jan 26, 2002·Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy·H Tomioka
Mar 19, 2002·Antimicrobial Agents and Chemotherapy·Enrique J Alvirez-FreitesMichael H Cynamon
Jun 5, 2002·American Journal of Respiratory and Critical Care Medicine·Naomi N BockUNKNOWN Tuberculosis Trials Consortium, Centers for Disease Control and Prevention, Atlanta, Georgia
Sep 25, 2002·International Journal of Pharmaceutics·Craig DunbarRick Batycky
Oct 18, 2002·Lancet·P Bernard FourieJohn L Johnson
Jan 25, 2003·Antimicrobial Agents and Chemotherapy·Yanmin HuDenis A Mitchison
Mar 27, 2003·Drugs·Bjørn Blomberg, Bernard Fourie
Citations
Jul 17, 2007·Biochemistry·Xinxin YangNicole S Sampson
Feb 23, 2012·The Journal of Biological Chemistry·Jared D SharpNancy A Woychik
Dec 17, 2008·Antimicrobial Agents and Chemotherapy·Jossy van den BoogaardRob E Aarnoutse
Mar 17, 2010·Antimicrobial Agents and Chemotherapy·Carmen A Molina-TorresLucio Vera-Cabrera
Apr 3, 2020·Molecular Biotechnology·Madhurima RoyAmit Kumar Das
Sep 19, 2006·Lancet·Dan AgranoffSanjeev Krishna